Device Trial Radar · NCT07941531
T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2032
Study completion Dec 2034
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD7 negative T-cells expressing CD7-CARs (CD7-CAR T cells) in pediatric patients with recurrent/refractory CD7+ hematological malignancies after lymphodepleting chemotherapy. Secondary Objectives: To evaluate the antileukemic activity of CD7-CAR T cells. As a phase I study, efficacy is not the primary objective of this study, but remains an important outcome to evaluate. We will determine the anti-leukemic activity of the CD7-CAR T cells in the bone marrow and in the treatment of extramedullary disease.
Conditions
- Lymphoma
- AML
- T-ALL
- Hematologic Malignancy
Interventions
FludarabineDrug
Day 4, 3, 2 at 40 mg/m2 dose. Intravenous.
CyclophosphamideDrug
Day -2 at 90mg/m2 dose. Intravenous infusion.
CliniMACSDevice
CD7-CAR T-cell infusion
MesnaDrug
Given intravenously divided as 4 doses equal to 25% cyclophosphamide dose per dose of Mesna administered prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm A)Time frame: up to 4 weeks after CD7CAR T-cell infusion
- Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm B)Time frame: up to 4 weeks after CD7CAR T-cell infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Jude Children's Research Hospital
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.